MEDIA

Media Inquiries

Investors@OncoSec.com

855-662-6732

Press Releases

VIEW ALL PRESS RELEASES

Video Feed

3D MOA Animation video

✕

OncoSec's VLA 3D MOA Animation

✕

TAVO Demonstration with Dr Algazi

✕

OncoSec at 2020 BIO CEO Panel

✕

Tumor Immunogenicity

✕

IAD Reel

✕

IAD Robert Andtbacka, M.D.

✕

Social Media

Twitter Feed

OncoSec Medical@OncoSec·
6h

Check out this @oncologytube interview featuring Melinda Telli, M.D. and Erika J. Crosby, Ph.D. to learn more about the pre-clinical data in triple-negative #BreastCancer that we presented at #SITC2020: http://bit.ly/3oIkRrl

OncoSec Medical@OncoSec·
19 Jan

Today we entered into an agreement granting @SirtexMedical an option to co-promote our lead investigational product candidate in anti-PD-1 checkpoint refractory metastatic #melanoma. Learn more here: https://bit.ly/3bPcVkZ #BiotechNews #cancer

OncoSec Medical@OncoSec·
14 Jan

#ICYMI, we joined @TNBCFoundation and @touchbbca in supporting the @BlackDOCTORS event, "The Doctor Is In," where experts in #BreastCancer gave a medical update from #SABCS2020. To watch a replay of the event, click here: http://bit.ly/2W2Tw77

OncoSec Medical@OncoSec·
12 Jan

Adil Daud, M.D., trial investigator of our Phase 2b KEYNOTE-695 #ClinicalTrial, spoke with @oncologytube about the interim data we presented at #SITC2020 in patients with anti-PD-1 refractory advanced #melanoma. Watch the interview here: http://bit.ly/2KkWEs4

Featured Articles

Melanoma Research Alliance

From Dermatology to Treatment: Second Opinions, Clinical Trials & becoming Your Own Best Advocate

PharmaVoice

Women of the Week interview with OncoSec’s Chief Clinical Development Officer, Kellie Malloy Foerter

Annals of Oncology

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

Clinical Cancer Research

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.